VENENUM Biodesign, a member of Genesis Biotechnology Group, is a drug discovery company focused on discovering new drug targets and innovative new medicines for diseases. Our approach is to bring our products to patients through clinical and commercial partnerships.

Hager Biosciences is a privately-owned biopharmaceutical company established by experienced medicinal chemists to provide pre-clinical therapeutic leads and candidates through operationally agile & effective drug discovery chemistry platforms for the pharmaceutical and biotech industries.My Experience:Responsible for synthesis, purification and characterization of a series of opioid receptor modulators for assay analyses.• Implemented several improvements to the development of synthetic processes.• Created detailed technical reports to update clients on research progress and the appropriate next steps.o Successfully recorded and interpreted research-derived data to advance client’s understanding.

Synthetic Organic / Medicinal Chemistry research towards the discovery of pharmaceuticals that target multidrug-resistant bacteria, such as methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus (VRE).My Experience:Responsible for synthesis, purification and characterization of antibiotic pro-drugs for analyses in assays.• Composed several synthetic experimental procedures and compiled research data for a patent applicationo Prepared and delivered weekly research progress presenations to direct future management activities• Provided client support for aspects of proper mass spectrometer usage and interpretation

•Contributed significantly to the discovery of a series compounds that were effective for the treatment of type II diabetes (hyperglycemia) and dyslipidemiao Created compounds that lowered concentrations of plasma glucose, total cholesterol and fatty acids by resolving issues related to the activity of chiral benzopyrancarboxylic acid intermediate compounds for the synthesis of enantiomeric Peroxizome Proliferator-Activated Receptor (PPAR) agonists.o Synthesized several larger highly-pure batches of PPAR agonists used for in vivo testing.o Compiled research data and composed detailed experimental procedures for a patent application.-Published research paper in the Journal of Medicinal Chemistry (2004, Vol. 47, No. 12)o Received Merck Excellence Award for discovering #242 and timely completion of the patent application.-Compound was chosen as a pre-clinical drug candidate o Created and delivered a well-received presentation for over 100 employees at a Merck symposium•Contributed significantly to the discovery of a series of p38-kinase inhibitor pyrrole derivatives that were effective for the treatment of asthma and COPD because they significantly inhibited airway inflammationo Designed, synthesized, purified and characterized a series of alkyl- and heterocycle-substituted thiadiazole derivative p38-kinase inhibitors for testing by biologists-Potent, inhalable compound MK-7708 was chosen as a pre-clinical drug candidate that is being marketed today for research purposeso Modified the pharmacokinetic characteristics to create a desirable inhaled drug profile – low oral bioavailability and elevated clearance for the serieso Collaborated on an improved, efficient synthetic route which increased the yield of multi-gram batches•Contributed significantly to the discovery of a sulfonylurea series of partial-PPAR agonists for the treatment of type II diabetes. These compounds reduced adverse effects while retaining effective anti-diabetic activity